Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo
- PMID: 21234531
- DOI: 10.1007/s00066-010-2116-3
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo
Abstract
Purpose: Cyclooxygenase-2 (COX-2) inhibitors mediate a systemic antitumor activity via antiangiogenesis and seem to enhance the response of primary tumors to radiation. Radiosensitizing effects of COX-2 inhibition have not been reported for bone metastases. Therefore, the aim of this study was the investigation of the radiosensitizing effects of the selective COX-2 inhibitor celecoxib in secondary bone tumors of a non-small cell lung carcinoma in vivo.
Materials and methods: Human A549 lung carcinomas were implanted into a cranial window preparation in male SCID mice (n = 24). Animals were treated with either celecoxib or radiation (7 Gy single photon dose) alone or a combination of celecoxib and radiation, respectively. Untreated animals served as controls. The impact of radiation and COX-2 inhibition on angiogenesis, microcirculation, and tumor growth was analyzed over 28 days by means of intravital microscopy and histological methods.
Results: Monotherapies with radiation as well as celecoxib had significant antitumor effects compared to untreated controls. Both therapies reduced tumor growth and vascularization to a similar extent. The simultaneous administration of celecoxib and radiation further enhanced the antitumor and antiangiogenic effects of single-beam radiation. With the combined treatment approach, tumor vascularization and tumor size were decreased by 57% and 51%, respectively, as compared to monotherapy with radiation.
Conclusion: The combined application of radiation therapy and COX-2 inhibition showed synergistic effects concerning the inhibition of tumor growth and tumor angiogenesis. Therefore, the combination of radiation with COX-2 inhibitor therapy represents a promising approach to improve the therapeutic efficacy of radiotherapy of bone metastases.
Similar articles
-
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.BMC Cancer. 2006 Jan 12;6:9. doi: 10.1186/1471-2407-6-9. BMC Cancer. 2006. PMID: 16409625 Free PMC article.
-
Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth.Am J Clin Oncol. 2003 Aug;26(4):S103-9. doi: 10.1097/01.COC.0000074147.22064.67. Am J Clin Oncol. 2003. PMID: 12902866
-
Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.Childs Nerv Syst. 2010 Nov;26(11):1605-12. doi: 10.1007/s00381-010-1190-2. Epub 2010 Jun 5. Childs Nerv Syst. 2010. PMID: 20526717
-
Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.Semin Oncol. 2004 Feb;31(1 Suppl 1):47-53. doi: 10.1053/j.seminoncol.2003.12.014. Semin Oncol. 2004. PMID: 14981580 Review.
-
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.Lung Cancer. 2003 Aug;41 Suppl 1:S115-21. doi: 10.1016/s0169-5002(03)00155-7. Lung Cancer. 2003. PMID: 12867070 Review.
Cited by
-
Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.Strahlenther Onkol. 2012 Feb;188(2):168-76. doi: 10.1007/s00066-011-0028-5. Epub 2012 Jan 18. Strahlenther Onkol. 2012. PMID: 22249335
-
Implantable Bioresponsive Hydrogel Prevents Local Recurrence of Breast Cancer by Enhancing Radiosensitivity.Front Bioeng Biotechnol. 2022 Apr 12;10:881544. doi: 10.3389/fbioe.2022.881544. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35497337 Free PMC article.
-
The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization.Strahlenther Onkol. 2012 Mar;188(3):255-61. doi: 10.1007/s00066-011-0043-6. Epub 2012 Feb 11. Strahlenther Onkol. 2012. PMID: 22322869
-
Pathway analysis for drug repositioning based on public database mining.J Chem Inf Model. 2014 Feb 24;54(2):407-18. doi: 10.1021/ci4005354. Epub 2014 Feb 5. J Chem Inf Model. 2014. PMID: 24460210 Free PMC article.
-
2-Carbaborane-3-phenyl-1H-indoles--synthesis via McMurry reaction and cyclooxygenase (COX) inhibition activity.ChemMedChem. 2013 Feb;8(2):329-35. doi: 10.1002/cmdc.201200455. Epub 2013 Jan 9. ChemMedChem. 2013. PMID: 23303738 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials